Fosaprepitant triple prophylaxis lowers postoperative nausea after gynecologic laparoscopy
Postoperative nausea and vomiting remains one of the most common and most clinically disruptive complications after laparoscopic gynecologic surgery, especially in younger female patients receiving total intravenous anesthesia. In this single-center, double-blind randomized trial, adding fosaprepitant to a dual regimen of dexamethasone and palonosetron reduced the burden of postoperative nausea and vomiting in a high-risk cohort followed for the first 24 hours after surgery.
The study addressed a problem anesthesiologists recognize at the bedside: standard dual prophylaxis does not fully suppress emetic signaling in patients whose baseline risk is already high. Laparoscopic gynecologic procedures combine several triggers for nausea, including surgical stimulation, pneumoperitoneum, opioid exposure in many perioperative pathways, and a population-level susceptibility that is more common in women and in younger patients. By pairing agents that act across different emetic pathways, the trial tested whether a third drug could close the remaining gap left by dual therapy alone.
Trial design in a high-risk surgical population
Female patients aged 19 to 50 years with American Society of Anesthesiologists physical status I or II were enrolled between August 2023 and July 2025 for elective laparoscopic gynecologic surgery under total intravenous anesthesia. Participants were randomized to receive either dual prophylaxis with dexamethasone and palonosetron or triple prophylaxis with dexamethasone, palonosetron, and fosaprepitant. The trial was single-center and double-blind, a design that matters here because postoperative nausea is strongly shaped by expectations, rescue treatment thresholds, and subjective symptom reporting.
A total of 140 patients were analyzed. The primary endpoint was the incidence of PONV within 24 hours after surgery. In practical terms, that window captures the early period when anesthetic effects, surgical stress, and immediate recovery-phase factors overlap most intensely. It is also the period when a prevention strategy has the clearest chance to influence recovery, oral intake, discharge readiness, and patient comfort.
A clear reduction in 24-hour PONV
The main result was direct and clinically meaningful. Triple prophylaxis reduced the incidence of PONV during the first 24 hours after surgery compared with dual therapy: 27.1% versus 47.9%. The odds ratio was 0.38, with a 95% confidence interval of 0.19 to 0.78, and the finding reached statistical significance with _p_ = 0.008.
The magnitude of the difference is hard to ignore. Nearly half of the patients receiving dual therapy still experienced nausea or vomiting in the first postoperative day, while the triple regimen brought that proportion down to just over one in four. For patients, that difference can determine whether recovery feels manageable or miserable. For clinicians, it changes how often rescue antiemetics are needed and how confidently a standard prophylactic plan can be expected to perform in a high-risk surgical setting.
The result also fits the pharmacology. Palonosetron provides 5-HT3 receptor antagonism, dexamethasone contributes antiemetic activity through mechanisms that are still incompletely defined but well established in perioperative practice, and fosaprepitant blocks the neurokinin-1 pathway, which is central to substance P–mediated emesis. Covering multiple emetic pathways at once is especially logical in patients whose nausea risk is driven by more than one trigger, because single-pathway suppression rarely proves sufficient.
Why the triple regimen may matter in laparoscopic gynecology
The surgical context is not incidental. Laparoscopic gynecologic procedures are among the settings in which PONV prevention is often pursued aggressively, because the patient population is already enriched for several established risk factors. Total intravenous anesthesia is frequently selected in part to reduce emetogenic burden, yet this trial suggests that TIVA alone does not eliminate the need for layered prophylaxis when baseline risk remains high.
This is where the data have immediate bedside relevance. A regimen that reduces PONV from 47.9% to 27.1% changes the failure rate of prophylaxis in a setting where symptoms can delay eating, mobility, and discharge. The effect also supports a broader principle in perioperative medicine: when the biologic drive for emesis is strong, relying on two agents may leave too much residual risk. A third mechanism can produce a more complete blockade of the emetic cascade.
The study does not offer a universal mandate for all surgical patients, and it does not need to. Its value lies in a specific, clearly defined population: young women undergoing laparoscopic gynecologic surgery under TIVA at a single center. In that group, the incremental benefit of fosaprepitant was large enough to shift the clinical balance toward triple prophylaxis.
What the findings do and do not settle
The trial establishes superiority for the triple regimen over the dual comparator on the prespecified 24-hour outcome, but it remains confined to one center and one operative context. The article does not provide broader data on different surgeries, different anesthetic techniques, or older patients, and those boundaries matter when translating results into general perioperative practice.
Even so, the clinical signal is strong because the intervention is mechanistically coherent and the endpoint is tightly linked to recovery quality. Nausea after surgery is not a trivial inconvenience; it is a symptom that can slow discharge, reduce oral intake, and worsen the entire postoperative experience. When a regimen suppresses that symptom more effectively without needing a fundamentally different anesthetic strategy, it gives perioperative teams a concrete option for patients at the highest risk.
The most defensible reading is straightforward: in this randomized cohort, adding fosaprepitant to dexamethasone and palonosetron improved 24-hour PONV prevention after laparoscopic gynecologic surgery under TIVA. What the report does not answer is whether the same benefit will hold across other high-risk operations, other recovery protocols, or broader patient groups outside this narrowly defined surgical population.